Dr. Eugene Bauer


Dr. Eugene A. Bauer is Founder, Chief Medical Officer and a member of the Board of Directors of Dermira, Inc. (Nasdaq: DERM), a development stage dermatology company. Dr. Bauer is also immediate-past President & Chief Medical Officer of Peplin, Inc., a position he held from 2008 to December 2009, when Peplin was acquired by LEO Pharma. Prior to Peplin, he was Chief Executive Officer of Neosil, Inc., also a development stage dermatology pharmaceutical company acquired by Peplin, Inc., in 2008. Dr. Bauer is Professor (Emeritus) in the School of Medicine at Stanford University and past Vice President for the Medical Affairs (1997-2001) and Dean of the School of Medicine (1995-2001) of Stanford University. Dr. Bauer received the M.D. degree from Northwestern University in 1967.

After 14 years on the faculty of Washington University School of Medicine, Dr. Bauer became Chair of the Department of Dermatology at Stanford University School of Medicine in 1988 and held this position for 7 years. A federally funded investigator for 25 years, Dr. Bauer served on review groups at the National Institutes of Health, including as chair of the AMS Study Section, as chair of GMA-1 Study Section, and as a member of the Advisory Council for the National Institute of Arthritis and Musculoskeletal and Skin Disease. He also served as a member of the Board of Scientific Counselors of the Division of Cancer Biology, Diagnosis and Centers of the National Cancer Institute.

Dr. Bauer is co-founder and a past member of the Board of Directors of Connetics Corp., a dermatology company acquired by Stiefel Laboratories in 2006. He is past Chairman of the Board of Directors of Medgenics, Inc. (NYSE: MDGN, now Aevi Genomic Medicine: GNMX), and a member of the boards of directors of Kadmon Corp. (Nasdaq: KDMN) and of several privately held companies. He has been elected to several honorific societies, including the National Academy of Medicine to which he was elected in 1997.